Swedish Orphan Biovitrum AB (publ)
STO:SOBI

Watchlist Manager
Swedish Orphan Biovitrum AB (publ) Logo
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
Watchlist
Price: 290 SEK -0.21% Market Closed
Market Cap: 99.8B SEK
Have any thoughts about
Swedish Orphan Biovitrum AB (publ)?
Write Note

Swedish Orphan Biovitrum AB (publ)
Other Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Swedish Orphan Biovitrum AB (publ)
Other Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
Other Current Liabilities
kr6.4B
CAGR 3-Years
9%
CAGR 5-Years
11%
CAGR 10-Years
24%
Biogaia AB
STO:BIOG B
Other Current Liabilities
kr51.3m
CAGR 3-Years
19%
CAGR 5-Years
-1%
CAGR 10-Years
N/A
Bonesupport Holding AB
STO:BONEX
Other Current Liabilities
kr91.1m
CAGR 3-Years
42%
CAGR 5-Years
16%
CAGR 10-Years
N/A
Vitrolife AB
STO:VITR
Other Current Liabilities
kr192m
CAGR 3-Years
48%
CAGR 5-Years
27%
CAGR 10-Years
9%
Probi AB
STO:PROB
Other Current Liabilities
kr35.4m
CAGR 3-Years
8%
CAGR 5-Years
-5%
CAGR 10-Years
5%
BioArctic AB
STO:BIOA B
Other Current Liabilities
kr49.3m
CAGR 3-Years
-17%
CAGR 5-Years
-32%
CAGR 10-Years
N/A
No Stocks Found

Swedish Orphan Biovitrum AB (publ)
Glance View

Market Cap
99.6B SEK
Industry
Biotechnology

Swedish Orphan Biovitrum AB (publ), often referred to as Sobi, is a biopharmaceutical company that has carved a niche in the development and commercialization of innovative treatments for rare diseases, primarily focusing on hematology, immunology, and specialty care. Founded in 2001 and headquartered in Stockholm, Sobi has garnered a reputation for its commitment to improving the lives of patients with complex medical conditions. The company's portfolio includes several key products that address unmet medical needs, particularly in areas such as hemophilia and other inherited disorders. Through strategic partnerships and acquisitions, Sobi has expanded its capabilities, bolstering its research and development pipeline while strengthening its market presence across Europe, North America, and beyond. As an investor, Sobi presents a compelling opportunity in the growing field of rare diseases, bolstered by a robust regulatory framework that often allows for expedited approval processes for groundbreaking therapies. The company’s focus on precision medicine and its dedication to patient-centric care position it well in an industry characterized by high demand and limited competition. With a solid financial foundation and a proactive approach to innovation, Sobi is poised to capture significant market share in a rapidly evolving landscape. Furthermore, with its strategic initiatives in expanding global reach and investing in next-generation therapies, Sobi exemplifies the principles of value investing by aligning long-term growth potential with the increasing need for specialized medical treatments.

SOBI Intrinsic Value
368.27 SEK
Undervaluation 21%
Intrinsic Value
Price

See Also

What is Swedish Orphan Biovitrum AB (publ)'s Other Current Liabilities?
Other Current Liabilities
6.4B SEK

Based on the financial report for Sep 30, 2024, Swedish Orphan Biovitrum AB (publ)'s Other Current Liabilities amounts to 6.4B SEK.

What is Swedish Orphan Biovitrum AB (publ)'s Other Current Liabilities growth rate?
Other Current Liabilities CAGR 10Y
24%

Over the last year, the Other Current Liabilities growth was -31%. The average annual Other Current Liabilities growth rates for Swedish Orphan Biovitrum AB (publ) have been 9% over the past three years , 11% over the past five years , and 24% over the past ten years .

Back to Top